Search

Displaying results 4301 - 4310 of 7502 in total
  1. Drug

    AIT-034

    go.drugbank.com/drugs/DB06106
    Experimental

    not respond to Neotrofin. … AIT-034 does not induce the production of NGF, and its mechanism of action is therefore believed to be different than Neotrofin.

  2. Drug

    KP1237

    go.drugbank.com/drugs/DB18401
    Experimental

    KP1237 is a antibody-redirecting molecule composed of two binding sites (a CD38 binder and a universal antibody binding terminus binder) connected by a linker chain.

  3. Drug

    EVT 201

    go.drugbank.com/drugs/DB05721
    Investigational

    It is being developed by Evotec Inc.

  4. Drug

    Perflutren

    go.drugbank.com/drugs/DB00556
    ApprovedInvestigational

    When exposed to ultrasound waves, the microspheres resonate and "echo" strong signals back to the ultrasound machine. … Perflutren, a diagnostic drug that is intended to be used for contrast enhancement during the indicated echocardiographic procedures, is comprised of lipid-coated microspheres filled with octafluoropropane

  5. Drug

    Lucanthone

    go.drugbank.com/drugs/DB04967
    Investigational

    One of the schistosomicides, it has been replaced largely by hycanthone and more recently praziquantel. (From Martindale The Extrapharmacopoeia, 30th ed., p46).

  6. Drug

    Nigericin

    go.drugbank.com/drugs/DB14056
    Experimental

    It is produced by Streptomyces hygroscopicus. (From Merck Index, 11th ed)

  7. Drug

    Autologous Hematopoietic Peripheral Blood Stem Cells

    go.drugbank.com/drugs/DB17067
    Investigational

    Autologous hematopoietic peripheral blood stem cells were tested in a clinical trial (NCT00424489) by Northwestern University for the treatment of refractory myasthenia gravis.

  8. Drug

    REC-994

    go.drugbank.com/drugs/DB15616
    Investigational

    REC-994 was cleared by the FDA in July, 2018 for a phase I trial for the treatment of cerebral cavernous malformation (CCM).

  9. Drug

    VaxSyn

    go.drugbank.com/drugs/DB17827
    Investigational

    VaxSyn HIV-1 is a recombinant form of the HIV envelope protein gp 160 developed by MicroGeneSys and the National Institute of Allergy and Infectious Diseases (NIAID).

  10. Drug

    ENTR-601-44

    go.drugbank.com/drugs/DB17836
    Investigational

    Developed by Entrada Therapeutics, it was investigated for the treatment of Duchenne muscular dystrophy.[L46641]